• 1
    Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 70415.
  • 2
    Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 36674.
  • 3
    Font J, Cervera R, López-Soto A, Pallarés L, Bosch X, Ampurdanés S, et al. Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations. Clin Rheumatol 1989; 8: 47583.
  • 4
    Roubey RA. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 144454.
  • 5
    McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87: 41204.
  • 6
    Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 15447.
  • 7
    Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 1778.
  • 8
    Wurm H. Beta 2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 5115.
  • 9
    Kochl S, Fresser F, Lobentanz E, Baier G, Utermann G. Novel interaction of apolipoprotein(a) with beta-2 glycoprotein I mediated by the kringle IV domain. Blood 1997; 90: 14829.
  • 10
    Nimpf J, Wurm H, Kostner GM. Interaction of beta 2-glycoprotein-I with human blood platelets: influence upon ADP-induced aggregation. Thromb Haemost 1985; 54: 397401.
  • 11
    Schousboe I. Beta-2 glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 108691.
  • 12
    Nimpf J, Bevers EM, Bomans PH, Till U, Wurm H, Kostner GM, et al. Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim Biophys Acta 1986; 884: 1429.
  • 13
    Keeling DM, Wilson AJG, Mackie IJ, Isenberg DA, Machin SJ. Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro. J Clin Pathol 1993; 46: 90811.
  • 14
    Bancsi LF, van der Linden IK, Bertina RM. Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67: 64953.
  • 15
    Arnout J, Vermylen J. Mechanisms of action of beta-2 glycoprotein I-dependent lupus anticoagulants. Lupus 1998; 7 Suppl 2: 238.
  • 16
    De Benedetti E, Reber G, Miescher PA, de Moerloose P. No increase of beta 2-glycoprotein I levels in patients with antiphospholipid antibodies [letter]. Thromb Haemost 1992; 68: 624.
  • 17
    Escolar G, Font J, Reverter JC, López-Soto A, Garrido M, Cervera R, et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation: studies in a perfusion system. Arterioscler Thromb 1992; 12: 196200.
  • 18
    Reverter JC, Tàssies D, Escolar G, Font J, López-Soto A, Ingelmo M, et al. Effect of plasma from patients with primary antiphospholipid syndrome on platelet function in a collagen rich perfusion system. Thromb Haemost 1995; 73: 1327.
  • 19
    Reverter JC, Tàssies D, Font J, Khamashta M, Ichikawa K, Cervera R, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998; 41: 14207.
  • 20
    Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J Clin Invest 1996; 98: 86374.
  • 21
    Wang MX, Kandiah DA, Ichikawa K, Khamashta M, Hughes G, Koike T, et al. Epitope specificity of monoclonal anti-beta 2 glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol 1995; 155: 162936.
  • 22
    Ichikawa K, Khamashta MA, Koike T, Matsuura E, Hughes GR. β2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 145361.
  • 23
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 24
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 25
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 26
    Gallart T, Benito C, Reverter JC, Bosch F, Blay M, Tàssies D, et al. True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. Br J Haematol 2002; 116: 87586.
  • 27
    De la Fuente MA, Egile C, Pereira A, Juan M, Vivanco F, Roelcke D, et al. Characterization of a monoclonal IgMK (IgMGAS) anti-Gd cold agglutinin (CA): its coexistence with a monoclonal IgG3K (IgGGAS) without CA activity that might be clonally related to IgMGAS. Blood 1994; 83: 131022.
  • 28
    Muñoz A, Gallart T, Usac EF, Fernandez-Alvarez J, Viñas O, Somoza N, et al. Anti-islet cell and anti-insulin antibody production by CD5+ and CD5− B lymphocytes in IDDM. Diabetologia 1995; 38: 6272.
  • 29
    Gallart T, Roelcke D, Blay M, Pereira A, Martinez A, Masso O, et al. Anti-Sia-lb (anti-Gd) cold agglutinins bind the domain NeuNAc alpha2-3Gal in sialyl Lewis(x), sialyl Lewis(a), and related carbohydrates on nucleated cells and in soluble cancer-associated mucins. Blood 1997; 90: 157687.
  • 30
    Baumgartner HR, Muggli R. Platelet adhesion and aggregation: morphological demonstration and quantitation in vivo and in vitro. In: GordonJL, editor. Platelets in biology and pathology. Amsterdam: Noth-Holland Publishing; 1976. p. 2360.
  • 31
    Baumgartner HR. Platelet interaction with collagen fibrils in flowing blood. I. Reaction of human platelets with alpha-chymotrypsin-digested subendothelium. Thromb Haemost 1977; 37: 116.
  • 32
    Escolar G, Bastida E, Castillo R, Ordinas A. Development of a computer program to analyze the parameters of platelet-vessel wall interaction. Haemostasis 1986; 16: 814.
  • 33
    Dunnet CW. New tables for multiple comparisons with a control. Biometrics 1964; 20: 48291.
  • 34
    McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193280.
  • 35
    Bakimer R, Fishman P, Blank M, Sredni D, Djaldetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody. J Clin Invest 1992; 89: 155863.
  • 36
    Machin SJ. Platelets and antiphospholipid antibodies. Lupus 1996; 5: 3867.
  • 37
    Chong BH, Brighton TC, Chesterman CN. Antiphospholipid antibodies and platelets. Semin Thromb Hemost 1995; 21: 7684.
  • 38
    McMillan R. Clinical role of antiplatelet antibody assays. Semin Thromb Hemost 1995; 21: 3745.
  • 39
    Anderson CL, Chacko GW, Osborne JM, Brandt JT. The Fc receptor for immunoglobulin G (Fc gamma RII) on human platelets. Semin Thromb Hemost 1995; 21: 19.
  • 40
    De Reys S, Blom C, Lepoudre B, Declerck PJ, De Ley M, Vermylen J, et al. Human platelet aggregation by murine monoclonal antibodies is subtype-dependent. Blood 1993; 81: 1792800.
  • 41
    Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ, et al. Immune mediated mechanisms for thrombosis: antiphospholipid binding to platelet membranes. Ann Rheum Dis 1988; 47: 84954.
  • 42
    Shi W, Chong BH, Chesterman CN. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81: 125562.
  • 43
    Joseph JE, Donohoe S, Harrison P, Mackie IJ, Machin SJ. Platelet activation and turnover in the primary antiphospholipid syndrome. Lupus 1998; 7: 33340.
  • 44
    Arvieux J, Roussel B, Pouzol P, Colomb MG. Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I. Thromb Haemost 1993; 70: 33641.
  • 45
    Martinuzzo ME, Maclouf J, Carreras LO, Lèvy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70: 66771.
  • 46
    Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation. Thromb Haemost 1995; 73: 52934.
  • 47
    Vermylen J, Hoylaerts MF, Arnout J. Antibody-mediated thrombosis. Thromb Haemost 1997; 78: 4206.
  • 48
    Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75: 53641.
  • 49
    Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost 1992; 68: 956.
  • 50
    Tomer A. A sensitivity and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 1997; 98: 64856.
  • 51
    Ford I, Urbaniak S, Greaves M. IgG from patients with antiphospholipid syndrome binds to platelets without induction of platelet activation. Br J Haematol 1998; 102: 8419.
  • 52
    Haga HJ, Christopoulos C, Machin SJ, Khamashta MA, Hughes GR. Lack of specific binding of anticardiolipin antibodies to intact platelets. Lupus 1992; 1: 38790.
  • 53
    Oosting JD, Derksen RH, Blokzijl L, Sixma JJ, de Groot PG. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity: studies in a thrombosis model. Thromb Haemost 1992; 68: 27884.
  • 54
    Schick PK, Kurica KB, Chacko GK. Location of phosphatidylethanolamine and phosphatidylserine in the human plasma platelet membrane. J Clin Invest 1976; 57: 12216.
  • 55
    Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane: studies in Scott syndrome, an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 1704957.
  • 56
    Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RFA. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 1993; 83: 46672.
  • 57
    Zwaal RFA, Bevers EM. Platelet phospholipid asymmetry and its significance in hemostasis. Subcell Biochem 1983; 9: 299334.
  • 58
    Bevers EM, Comfurius P, van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Bichem 1982; 122: 42936.
  • 59
    McCrae KR, Shattil SJ, Cines DB. Platelet activation induces increased Fc gamma receptor expression. J Immunol 1990; 144: 39207.
  • 60
    Roubey RA, Eisenberg RA, Harper MF, Winfield JB. “Anticardiolipin” autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid: importance of Ag density and bivalent binding. J Immunol 1995; 154: 95460.
  • 61
    Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 45762.
  • 62
    Wagenknecht DR, McIntyre JA. Changes in beta 2-glycoprotein I antigenicity induced by phospholipid binding. Thromb Haemost 1993; 69: 3615.
  • 63
    Davis WD, Brey RL, Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992; 10: 45560.
  • 64
    Shibata S, Sasaki T, Hirabayashi Y, Seino J, Okamura K, Yoshinaga K, et al. Risk factors in the pregnancy of patients with systemic lupus erythematosus: association of hypocomplementemia with poor prognosis. Ann Rheum Dis 1992; 51: 61923.
  • 65
    Santiago MB, Gaburo N Jr, de Oliveira RM, Cossermelli W. Complement activation by anticardiolipin antibodies. Ann Rheum Dis 1991; 50: 24950.
  • 66
    Rinder CS, Rinder HM, Smith BR, Ficht JC, Smith MJ, Tracey JB, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995; 96: 156472.
  • 67
    Chang CP, Zhao J, Wiedmer T, Sims PJ. Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine. J Biol Chem 1993; 268: 71718.
  • 68
    Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 21120.